Ultragenyx to Host Conference Call for First Quarter 2021 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced a conference call scheduled for May 4, 2021, at 5 PM ET, to discuss its Q1 financial results for the period ending March 31, 2021. The call will be accessible via the company website and phone. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases and has a diverse portfolio of approved treatments. The management team emphasizes efficient drug development to meet urgent patient needs.

Positive

• Ultragenyx is committed to developing therapies for rare diseases with high unmet medical needs.
• The company has a diverse portfolio of approved therapies and product candidates.

Negative

• None.

NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4, 2021 at 5pm ET to discuss its financial results and corporate update for the first quarter ended March 31, 2021.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 6883837. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at:
www.ultragenyx.com

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370

FAQ

When is Ultragenyx's next earnings call?

Ultragenyx's next earnings call is scheduled for May 4, 2021, at 5 PM ET.

What financial results will Ultragenyx discuss on May 4, 2021?

Ultragenyx will discuss its financial results for the first quarter ended March 31, 2021.

How can investors access the Ultragenyx conference call?

Investors can access the conference call by phone at (855) 797-6910 or online via the company's website.